Literature DB >> 18226725

Nitrous oxide-oxygen mixture during care of bedsores and painful ulcers in the elderly: a randomized, crossover, open-label pilot study.

Adeline Paris1, Rémi Horvath, Pierre Basset, Stéphane Thiery, Pascal Couturier, Alain Franco, Jean-Luc Bosson.   

Abstract

Bedsore and ulcer care can often be painful and no standardized analgesic method exists today for pain relief during treatment in adults and the elderly. To evaluate the analgesic efficacy of a nitrous oxide-oxygen mixture vs. morphine during painful bedsore and ulcer care in adult and elderly patients, we conducted a randomized, crossover, multicenter, prospective, open-label, pilot study. Thirty-four inpatients, aged 53-96 years (median 84 years), were recruited in Grenoble University Hospital, Annecy Hospital and Chambéry Hospital, France, from January to June 2001. Each of the 34 patients received morphine (M), nitrous oxide-oxygen mixture (E), or morphine+nitrous oxide-oxygen mixture (ME) during painful care in a crossover protocol. Treatments were changed every two days and the study duration was six days. Analgesia was evaluated before and after each care session using a behavioral scale to evaluate pain in noncommunicating adults (ECPA), a visual analog scale (VAS), a global hetero-evaluation scale (GHES), and the DOLOPLUS-2 scale. There was a significant overall difference (P<0.01) among the three treatments. On the ECPA, the average difference after and before care was +5.2+/-8.6 (M), -0.3+/-8 (E), and -0.6+/-7.4 (ME), respectively. There was a significant difference between M and E, and M and ME (each P<0.01). No difference was found between E and ME (P=0.97). There were similar significant differences in the GHES and DOLOPLUS-2 scales (all tests P<0.01). Post hoc comparisons showed a significant difference (P<0.01) between M and E, and between M and ME without any additional effect for M+E. No differences were found with regard to safety or tolerability. This pilot study demonstrates the superiority of nitrous oxide-oxygen mixture over morphine for analgesia. This experience suggests that this mixture has ease of use, rapid effect, and limited contraindications when used during painful bedsore and ulcer care in elderly patients. Furthermore, it is well accepted by these patients and by nursing staff.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18226725     DOI: 10.1016/j.jpainsymman.2007.03.014

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  5 in total

Review 1.  Breakthrough pain in elderly patients with cancer: treatment options.

Authors:  Sophie Pautex; Nicole Vogt-Ferrier; Gilbert B Zulian
Journal:  Drugs Aging       Date:  2014-06       Impact factor: 3.923

Review 2.  Minimising wound-related pain at dressing change: evidence-informed practice.

Authors:  Kevin Y Woo; Keith Harding; Patricia Price; Gary Sibbald
Journal:  Int Wound J       Date:  2008-06       Impact factor: 3.315

3.  Evaluation of the efficacy of nitrous oxide inhalation sedation on anxiety and pain levels of patients undergoing endodontic treatment in a vital tooth: A prospective randomized controlled trial.

Authors:  Pallvi Dhand Gupta; Pardeep Mahajan; Prashant Monga; Deepa Thaman; Vineet I S Khinda; Amit Gupta
Journal:  J Conserv Dent       Date:  2019 Jul-Aug

4.  Nitrous Oxide/Oxygen Effect on IANB Injection Pain and Mandibular Pulpal Anesthesia in Asymptomatic Subjects.

Authors:  Ben Kushnir; Sara Fowler; Melissa Drum; John Nusstein; Al Reader; Mike Beck Dds
Journal:  Anesth Prog       Date:  2021-06-01

5.  Nitrous oxide/oxygen plus acetaminophen versus morphine in ST elevation myocardial infarction: open-label, cluster-randomized, non-inferiority study.

Authors:  Sandrine Charpentier; Michel Galinski; Vincent Bounes; Agnès Ricard-Hibon; Carlos El-Khoury; Meyer Elbaz; François-Xavier Ageron; Stéphane Manzo-Silberman; Louis Soulat; Frédéric Lapostolle; Alexandre Gérard; Delphine Bregeaud; Vanina Bongard; Eric Bonnefoy-Cudraz
Journal:  Scand J Trauma Resusc Emerg Med       Date:  2020-05-12       Impact factor: 2.953

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.